Related Experiment Video
Updated: Jan 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Identification of key genes and specific pathways potentially involved in androgen-independent,
Sha Zhu1, Lili Jiang1,2, Liuyan Wang3
1Department of Immunology, Collaborative Innovation Center of Cancer Chemoprevention, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China, chzsha06@126.com.
Background:
Resistance to mitoxantrone (MTX), an anthracenedione antineoplastic agent used in advanced and metastatic androgen-refractory prostate cancer (PCa), seriously limits therapeutic success.
Methods:
Xenografts from two human PCa cell lines (VCaP and CWR22) were established in male severe combined immunodeficiency mice, and MTX was administered, with or without concurrent castration, three times a week until tumors relapsed. Microarray technology was used to screen for differentially expressed genes (DEGs) in androgen-independent, MTX-resistant PCa xenografts. Gene expression profiles of MTX-treatment xenografts and their respective parental cell lines were performed using an Agilent whole human genome oligonucleotide microarray and analyzed using Ingenuity Pathway Analysis software.
Results:
A total of 636 genes were differentially expressed (fold change ≥1.5; P<0.05) in MTX-resistant castration-resistant prostate cancer (CRPC) xenografts. Of these, 18 were selected to be validated and showed that most of these genes exhibited a transcriptional profile similar to that seen in the microarray (Pearson's r=0.87). Western blotting conducted with a subset of genes deregulated in MTX-resistant CRPC tumors was shown through network analysis to be involved in androgen synthesis, drug efflux, ATP synthesis, and vascularization.
Conclusion:
The present data provide insight into the genetic alterations underlying MTX resistance in androgen-independent PCa and highlight potential targets to improve therapeutic outcomes.
Insights
Mitoxantrone resistance in prostate cancer (PCa) is a major challenge. This study identified 636 differentially expressed genes in resistant tumors, revealing potential targets for improved therapy.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Androgen-refractory prostate cancer (PCa) treatment is limited by resistance to mitoxantrone (MTX).
- Understanding the genetic basis of MTX resistance is crucial for developing effective therapies.
Purpose of the Study:
- To identify genetic alterations associated with MTX resistance in androgen-independent PCa.
- To explore potential therapeutic targets for overcoming MTX resistance.
Main Methods:
- Established human PCa xenografts (VCaP, CWR22) in immunodeficient mice.
- Administered MTX with or without castration until tumor relapse.
- Utilized microarray technology to screen for differentially expressed genes (DEGs) and Ingenuity Pathway Analysis for data interpretation.
Main Results:
- Identified 636 DEGs (fold change ≥1.5; P<0.05) in MTX-resistant castration-resistant PCa (CRPC) xenografts.
- Validated 18 DEGs, showing high correlation with microarray data (Pearson's r=0.87).
- Network analysis revealed deregulated genes involved in androgen synthesis, drug efflux, ATP synthesis, and vascularization.
Conclusions:
- The study provides insights into the genetic mechanisms of MTX resistance in advanced PCa.
- Identified key pathways and genes that represent potential targets for overcoming therapeutic resistance.
Related Concept Videos
Cell Specific Gene Expression
Cell Specific Gene Expression
Treatment Resistant Cancers
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
Key Elements for Plant Nutrition
Introduction to Test of Independence
The test statistic for a test of independence is similar to that of a goodness-of-fit test:

